NCT07385235

Compare and Evaluate the Safety and PK Data of a Single Dose Administration of 'AD-115A' or 'AD-1151'

A Randomized, Open-label, Single-dose, Two-sequence, and Two-period Crossover Study to Evaluate the Pharmacokinetics and Safety Between the Administration of AD-115A and the Administration of AD-1151 for Healthy Subjects in Fasting State

• Status: Recruiting
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 46 (estimated)
• Sponsor: Addpharma Inc. · Industry
• Sex: All
• Age: 19 Years
• Healthy volunteers: Not accepted

Summary

The study compare and evaluate the safety and pharmacokinetic characteristics of a single dose administration of 'AD-115A' or 'AD-1151' in healthy adults.

Detailed description

A randomized, open-label, single-dose, two-sequence, and two-period crossover study to evaluate the pharmacokinetics and safety between the administration of AD-115A and the administration of AD-1151 for healthy subjects in fasting state

Conditions

• Gastric Ulcer

Interventions

Type	Name	Description
DRUG	AD-115A, AD-1151	Single-dose oral administration of AD-115A or AD-1151 (200 mg tablet), according to randomized sequence.

Timeline

• Start date: 2026-01-27
• Primary completion: 2026-03-07
• Completion: 2026-03-16
• First posted: 2026-02-04
• Last updated: 2026-02-11

Locations

1 site across 1 country: South Korea